According to results from EMREROR-reduced trial, higher baseline NT-proBNP concentrations were associated with greater risk for adverse heart failure outcomes, but empagliflozin reduced risk regardless of baseline NT-proBNP concentration [35]. Here, NPPB is linked to heart failure.